Coronary Artery Bypass Grafting, Coronary Artery Disease
Conditions
Keywords
CABG, melatonin, inflammation
Brief summary
The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury . Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent. the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.
Detailed description
Myocardial ischemia is a situation where there is an inadequate blood and oxygen supply to the heart muscles due to partial or complete obstruction of the coronary arteries, predisposing the affected cardiac muscle to death. Hence, restoration of blood supply is critical to reestablish myocardial reperfusion. The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury . Strategies to improve the CABG related complications are much needed to augment the positive outcomes in the post-operative surviving patients. There are various therapeutic approaches to decrease or ameliorate myocardial I/R injury, these include reperfusion controlling, cardioprotective events and management via various interventions. Melatonin (N-acetyl 5-methoxy-tryptamine) is mainly secreted by the pineal gland to regulate sleep. Since 1993 when melatonin was first reported, a wide range of melatonin functions have been directly confirmed by multiple scientific studies . Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent. Early studies have shown that melatonin exerts beneficial effects in the context of renal I/R, myocardial I/R, and hepatic I/R. The ability to protect against I/R injury may relate to the functions of melatonin as both an anti-inflammatory and an antioxidant agent . Some authors show an anti-apoptotic action of melatonin in different organs of the body, such as thymus, kidney, brain and liver . the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.
Interventions
DIETARY_SUPPLEMENTMelatonin
patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
OTHERplacebo
patients will receive capsules of the same size and color
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients who will undergo elective CABG, * ready to participate in the study and * can be reached by phone
Exclusion criteria
* • Patients who will require urgent surgery and won't have adequate time to take medications for 5 days, * Re-operative patients (CABG), * Off-pump CABG, * Patients who have concomitant renal failure, * Patients with severe respiratory problems. * Patients with previous stroke or significant cerebrovascular disease, * Patients with hepatitis b,c and HIV. * Inflammatory disease ex. Rheumatoid arthritis, psoriasis…, * Patients with ejection fraction (EF%) lower than 40%, * Patients undergo CABG surgery with simultaneous heart valve repair or replacement, resection of a ventricular aneurysm, or other operations. * Pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nuclear factor-kB (NF-κB) | 24 hours | Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor that is involved in inflammatory and immune responses, as well as in regulation of expression of many other genes related to cell survival, proliferation, and differentiation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| interleukin 6 il-6 | 24 hours | Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release. |
| Tumor necrosis factor alpha TNF-α | 24 hours | Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated heart diseases. |
| cardiac troponins | 24 hours | cardiac marker |
Other
| Measure | Time frame | Description |
|---|---|---|
| LVEF% | 24 hours | left ventricular ejection fraction |
| Safety (Adverse effects from melatonin) | 5 days | Safety of melatonin |
| hospital length of stay | 5-7 days | Duration of staying in hospital |
| ICU length of stay | 2-3 days | Duration of staying in ICU |
Contacts
Primary Contacteman A. casper, masters
Backup Contactsara M. Farid, PhD
Outcome results
None listed